NxStage Medical (NXTM) Receiving Somewhat Positive News Coverage, Accern Reports
News headlines about NxStage Medical (NASDAQ:NXTM) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NxStage Medical earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news headlines about the medical device company an impact score of 45.351555779079 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s rankings:
- NxStage Medical (NXTM) vs. Novadaq Technologies (NVDQ) Critical Analysis (americanbankingnews.com)
- AO Indicator Trending Lower For NxStage Medical Inc (NXTM) – Evergreen Caller (evergreencaller.com)
- NxStage Medical : Breakfast Technical Briefing on Medical Equipment Stocks — Prestige Brands, Smith & Nephew, Nxstage Medical, and Amedica (4-traders.com)
- Nxstage Medical Inc (NXTM): What are the Current Levels Showing? – Wall Street Review (thewallstreetreview.com)
- Breakfast Technical Briefing on Medical Equipment Stocks — Prestige Brands, Smith & Nephew, Nxstage Medical, and … – Markets Insider (markets.businessinsider.com)
A number of equities analysts have weighed in on the company. Leerink Swann lowered NxStage Medical from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $28.00 to $30.00 in a research note on Tuesday, August 22nd. BTIG Research lowered NxStage Medical from a “buy” rating to a “neutral” rating in a research note on Friday, August 11th. Zacks Investment Research lowered NxStage Medical from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Stephens lowered NxStage Medical from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $33.00 to $30.00 in a research note on Wednesday, August 9th. Finally, Jefferies Group LLC lowered NxStage Medical from a “buy” rating to a “hold” rating and decreased their target price for the stock from $33.00 to $30.00 in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating and nine have issued a hold rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $30.25.
NxStage Medical (NXTM) traded up 0.07% during trading on Tuesday, hitting $27.99. The stock had a trading volume of 70,708 shares. The company has a 50-day moving average of $26.55 and a 200 day moving average of $25.99. The firm’s market cap is $1.85 billion. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80.
NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.03). NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The business had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. During the same period last year, the firm earned ($0.03) earnings per share. The business’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts predict that NxStage Medical will post ($0.04) earnings per share for the current fiscal year.
In other news, President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $25.19, for a total value of $25,190.00. Following the sale, the president now directly owns 75,903 shares of the company’s stock, valued at $1,911,996.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $23.14, for a total value of $80,990.00. Following the completion of the sale, the senior vice president now directly owns 17,270 shares in the company, valued at $399,627.80. The disclosure for this sale can be found here. Insiders sold 53,900 shares of company stock worth $1,463,316 over the last ninety days. Insiders own 4.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “NxStage Medical (NXTM) Receiving Somewhat Positive News Coverage, Accern Reports” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://theolympiareport.com/2017/09/05/nxstage-medical-nxtm-receiving-somewhat-positive-news-coverage-accern-reports.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.